Chiara Tolassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chiara Tolassi has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Padovani
Department of clinical and experimental sciences University of Brescia Brescia Italy
8 shared publications - Andrea Pilotto
Department of clinical and experimental sciences University of Brescia Brescia Italy
6 shared publications - Irene Girotto
Department of Clinical and Experimental Sciences, Neurology Unit University of Brescia Brescia Italy
4 shared publications Caterina Martinuzzo
Department of Clinical and Experimental Sciences, Neurology Unit University of Brescia Brescia Italy
3 shared publications- Alessandro Rondina
Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Italy
2 shared publications - Alice Galli
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy
2 shared publications
Latest Publications
- 5 November 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (11)
Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel
Blood‐based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high‐multiplex platforms. Many biobanks consist predominantly of serum, whereas most current NUcleic‐acid‐Linked Immuno‐Sandwich Assay (NULISA) studies use plasma. We compared the 130‐protein NULISAseq central nervous system (CNS) Disease Panel head‐to‐head in matched serum and plasma collected at the same venipuncture from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired plasma‐minus‐serum difference (dNPQ). Concordance was moderate to high: 114 of 130 proteins reached FDR significance and 18 reached rho ≥ 0.90, with a median rho of 0.65 (range 0.010–0.988). Proteins were classified into three concordance tiers (31, 6 and 30 proteins), with the remaining 63 showing intermediate concordance. Cytoskeletal markers (NEFH rho = 0.988; NEFL rho = 0.947) and glial GFAP (rho = 0.949, |dNPQ| < 0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but showed a systematic plasma‐greater‐than‐serum offset (pTau‐181 rho = 0.869, dNPQ = +0.67; pTau‐217 rho = 0.846, dNPQ = +0.64; pTau‐231 rho = 0.885, dNPQ = +0.89). Platelet‐derived analytes (CD40LG rho = 0.102, dNPQ = −4.74; BDNF rho = 0.223, dNPQ = −2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau require matrix‐specific calibration, whereas amyloid peptides and platelet‐sensitive analytes cannot be reliably compared across matrices without strictly standardised pre‐analytical conditions. image
- 5 November 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (11)
Matrix Matters: Head‐To‐Head Concordance of Serum and Plasma for NULISAseq CNS Disease Panel
Blood‐based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high‐multiplex platforms. Many biobanks consist predominantly of serum, whereas most current NUcleic‐acid‐Linked Immuno‐Sandwich Assay (NULISA) studies use plasma. We compared the 130‐protein NULISAseq central nervous system (CNS) Disease Panel head‐to‐head in matched serum and plasma collected at the same venipuncture from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin's concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired plasma‐minus‐serum difference (dNPQ). Concordance was moderate to high: 114 of 130 proteins reached FDR significance and 18 reached rho ≥ 0.90, with a median rho of 0.65 (range 0.010–0.988). Proteins were classified into three concordance tiers (31, 6 and 30 proteins), with the remaining 63 showing intermediate concordance. Cytoskeletal markers (NEFH rho = 0.988; NEFL rho = 0.947) and glial GFAP (rho = 0.949, |dNPQ| < 0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but showed a systematic plasma‐greater‐than‐serum offset (pTau‐181 rho = 0.869, dNPQ = +0.67; pTau‐217 rho = 0.846, dNPQ = +0.64; pTau‐231 rho = 0.885, dNPQ = +0.89). Platelet‐derived analytes (CD40LG rho = 0.102, dNPQ = −4.74; BDNF rho = 0.223, dNPQ = −2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau require matrix‐specific calibration, whereas amyloid peptides and platelet‐sensitive analytes cannot be reliably compared across matrices without strictly standardised pre‐analytical conditions. image
- Open Access
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Network-based analyses identify GFAP as a cross-domain hub linking synaptic, neuronal, and inflammatory CSF markers in Alzheimer’s disease
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessNetwork-based analyses identify GFAP as a cross-domain hub linking synaptic, neuronal, and inflammatory CSF markers in Alzheimer’s disease
- Open Access
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Integrated NULISA-based CSF neuroimmune profiling reveals microglial–axonal injury signatures associated with early disability and NAWM damage in new-onset Multiple Sclerosis patients
BackgroundMultiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited. ObjectiveTo integrate high-sensitivity CSF biomarker profiling with clinical disability measures, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatmentnaïve new diagnosed Multiple Sclerosis patients.MethodsCSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched healthy controls. A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis was performed using false discovery rate (FDR) correction. Multivariable linear regression models adjusted for age, sex, and ethnicity were used to evaluate associations with baseline Expanded Disability Status Scale (EDSS), short-term clinical change after high-dose corticosteroid therapy (ΔEDSS) and MRI white matter lesion volume. Partial correlation analyses were performed to assess associations between CSF and diffusion MRI measures in NAWM regions of interest.ResultsSeven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NEFL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NFL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay.In multivariable models, higher levels of glial activation markers were independently associated with greater baseline disability. CSF NFL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, indicating that neuroaxonal injury reflects both focal inflammatory activity and diffuse microstructural damage beyond visible lesions.DiscussionThis application of ultra-sensitive NULISA multiplex CSF profiling in treatment-naïve MS at diagnosis demonstrates that multiple immunological and neurodegenerative pathways are simultaneously active at disease onset and are associated with early disability and microstructural white matter damage. These findings support the concept that inflammatory and neurodegenerative processes occur in parallel early in MS and suggest that integrated CSF biomarker profiling may improve early disease characterization.ConclusionsMultiplex CSF proteomic profiling using NULISA identifies biologically meaningful biomarker signatures at MS disease onset. Integration of multiplex biomarkers with clinical and imaging measures may improve early disease stratification and support personalized therapeutic strategies.
- 26 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIntegrated NULISA-based CSF neuroimmune profiling reveals microglial–axonal injury signatures associated with early disability and NAWM damage in new-onset Multiple Sclerosis patients
BackgroundMultiple sclerosis (MS) is characterized by inflammatory demyelination, neuroaxonal injury and progressive neurodegeneration. The biological processes driving the disease are already active at clinical onset, yet comprehensive characterization of different molecular pathways at diagnosis remains limited. ObjectiveTo integrate high-sensitivity CSF biomarker profiling with clinical disability measures, MRI lesion burden, and microstructural diffusion metrics in normal-appearing white matter (NAWM) in treatmentnaïve new diagnosed Multiple Sclerosis patients.MethodsCSF samples were collected from 70 treatment-naïve newly diagnosed MS patients and 11 age- and sex-matched healthy controls. A CNS Disease Panel of 120 CSF biomarkers was quantified using ultra-sensitive NULISA technology. Differential expression analysis was performed using false discovery rate (FDR) correction. Multivariable linear regression models adjusted for age, sex, and ethnicity were used to evaluate associations with baseline Expanded Disability Status Scale (EDSS), short-term clinical change after high-dose corticosteroid therapy (ΔEDSS) and MRI white matter lesion volume. Partial correlation analyses were performed to assess associations between CSF and diffusion MRI measures in NAWM regions of interest.ResultsSeven biomarkers were significantly increased in MS compared with controls after FDR correction: REST, IL-16, CHI3L1, NEFL, ICAM-1, TREM2, and CHIT1. Correlation analysis demonstrated clustering among markers of glial and innate immune activation (CHI3L1, TREM2, CHIT1) and moderate associations between NFL and glial markers. REST was strongly correlated with IL16, suggesting early transcriptional and immune pathway interplay.In multivariable models, higher levels of glial activation markers were independently associated with greater baseline disability. CSF NFL levels correlated with white matter lesion burden and were significantly associated with diffusion abnormalities in NAWM, particularly in the genu of the corpus callosum, cingulum, and anterior corona radiata, indicating that neuroaxonal injury reflects both focal inflammatory activity and diffuse microstructural damage beyond visible lesions.DiscussionThis application of ultra-sensitive NULISA multiplex CSF profiling in treatment-naïve MS at diagnosis demonstrates that multiple immunological and neurodegenerative pathways are simultaneously active at disease onset and are associated with early disability and microstructural white matter damage. These findings support the concept that inflammatory and neurodegenerative processes occur in parallel early in MS and suggest that integrated CSF biomarker profiling may improve early disease characterization.ConclusionsMultiplex CSF proteomic profiling using NULISA identifies biologically meaningful biomarker signatures at MS disease onset. Integration of multiplex biomarkers with clinical and imaging measures may improve early disease stratification and support personalized therapeutic strategies.
- Open Access
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Plasma p-tau isoform profiles identify biologically distinct severity strata in Alzheimer’s disease
Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPlasma p-tau isoform profiles identify biologically distinct severity strata in Alzheimer’s disease
Background: Plasma phosphorylated tau (p-tau) isoforms are established biomarkers of Alzheimer’s disease (AD), but whether their combined elevation reflects biological heterogeneity within AD remains unclear.Objective: To determine whether distinct plasma p-tau217, p-tau181, and p-tau231 profiles identify clinically and biologically meaningful severity strata within biologically confirmed AD.Methods: We included 106 patients with CSF-confirmed AD at the mild cognitive impairment or dementia stage. Participants underwent clinical assessment, CSF Aβ42 and tau biomarker measurement, and plasma assessment of p-tau217, p-tau181, p-tau231, Aβ42/Aβ40, GFAP, and NfL. Longitudinal MMSE data were available in 80 participants over a mean 2.6-year follow-up. Patients were classified using ROC-derived multi-isoform profiles and, separately, p-tau217 quintiles. Clinical and biological group differences and age- and sex-adjusted regression models were evaluated.Results: Multi-isoform profiling identified five profiles, ranging from all-intermediate p-tau isoforms to triple-high. Compared with the all-intermediate profile, profiles with broader p-tau isoform elevation showed higher CSF tau markers, higher plasma GFAP and NfL, and faster annualized MMSE decline. The triple-high profile showed worst cognitive performance and highest plasma biomarker burden. Complementary p-tau217 quintile stratification showed a parallel severity gradient, with higher quintiles associated with increased CSF tau markers, GFAP, NfL, and cognitive decline. Regression analyses supported p-tau217 as the strongest single-marker correlate, whereas p-tau231 contributed to NfL and CSF t-tau models.Conclusions: Multi-isoform plasma p-tau profiling identifies biologically distinct AD severity strata, consistent with a hierarchy of increasing tau phosphorylation burden. p-tau217 captures much of this continuum and remains the most robust single-marker correlate, whereas p-tau231 may provide complementary information on neurodegeneration-related biology.
- Open Access
Matrix matters: head-to-head concordance of serum and plasma for NULISAseq CNS Disease Panel
Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin’s concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions. Main Points: Across the 130-protein NULISAseq CNS Disease Panel, serum and plasma showed moderate-to-high overall concordance (median Spearman rho 0.72; 123/130 proteins significant). Neurofilaments (NEFH, NEFL) and GFAP were interchangeable between matrices, whereas phosphorylated tau species retained rank order but required matrix-specific calibration of absolute levels. Platelet-derived (CD40LG, BDNF) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) were not comparable across matrices without strict pre-analytical standardisation.
Open AccessMatrix matters: head-to-head concordance of serum and plasma for NULISAseq CNS Disease Panel
Blood-based proteomic profiling is now widely applied in neurodegenerative and neuroinflammatory disease, yet the choice between serum and plasma remains poorly characterised for high-multiplex platforms. Many legacy biobanks hold mainly serum, whereas most current NUcleic-acid-Linked Immuno-Sandwich Assay (NULISA) studies use plasma. We compared the 130-protein NULISAseq central nervous system (CNS) Disease Panel head-to-head in matched serum and plasma collected at the same draw from 62 participants (30 neurodegenerative, 19 demyelinating, 13 healthy controls). Agreement was measured with Spearman correlation (rho), Lin’s concordance correlation coefficient (CCC), the intraclass correlation coefficient (ICC) and the mean paired serum-to-plasma difference (dNPQ). Concordance was moderate to high: 123 of 130 proteins reached significance and 18 reached rho >= 0.90, with a median rho of 0.72 (range 0.10-0.988). Proteins fell into three tiers. Cytoskeletal markers (NEFH rho=0.988; NEFL rho=0.947) and glial GFAP (rho=0.949, |dNPQ|<0.5) were interchangeable between matrices. Phosphorylated tau (pTau) species retained excellent rank concordance but carried a systematic plasma-greater-than-serum offset (pTau-181 rho=0.869, dNPQ=+0.67; pTau-217 rho=0.846, dNPQ=+0.64; pTau-231 rho=0.885, dNPQ=+0.89). Platelet-derived analytes (CD40LG rho=0.102, dNPQ=-4.74; BDNF rho=0.223, dNPQ=-2.69) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) diverged markedly. For most clinically relevant neurodegeneration markers, especially cytoskeletal and glial proteins, serum is a valid substitute for plasma; absolute thresholds for phosphorylated tau and amyloid peptides require matrix-specific calibration, and platelet-sensitive analytes cannot be compared across matrices without strictly standardised pre-analytical conditions. Main Points: Across the 130-protein NULISAseq CNS Disease Panel, serum and plasma showed moderate-to-high overall concordance (median Spearman rho 0.72; 123/130 proteins significant). Neurofilaments (NEFH, NEFL) and GFAP were interchangeable between matrices, whereas phosphorylated tau species retained rank order but required matrix-specific calibration of absolute levels. Platelet-derived (CD40LG, BDNF) and intracellular synaptic proteins (NRGN, SNAP25, ENO2) were not comparable across matrices without strict pre-analytical standardisation.
- Open Access
- 31 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 172
Prognostic Significance of Triglyceride Glucose Index in Intracerebral Hemorrhage
Background: The triglyceride glucose index (TyG-i), a biomarker of insulin resistance, has been associated with adverse vascular outcomes and risk stratification in several cardiovascular and cerebrovascular phenotypes. However, data on TyG-i as a prognostic marker in spontaneous intracerebral hemorrhage (ICH) remain limited. Objective: To explore the association between TyG-i and 90-day functional outcome in patients with ICH. Methods: A retrospective analysis of adult patients admitted for non-traumatic small vessel disease-related ICH at three Italian neurological institutions was conducted. TyG-i was calculated on admission as Ln[(fast triglycerides (mg/dL) × fast glucose (mg/dL))]/2. Functional outcome was measured with the modified Rankin Scale (mRS) at 90 days from the index event. TyG-i was analyzed as a continuous variable and categorized in quintiles (Q1 to Q5). Predictors of poor outcome (mRS 4–6) were investigated with multivariable logistic regression. Results: A total of 463 patients were included, of whom 197 (42.5%) had poor outcome at 90 days. TyG-i analyzed as a continuous variable was not associated with unfavorable prognosis. TyG-i analyzed as a categorical variable stratified by quintiles showed a non-linear U-shaped relationship with functional outcome; patients in Q4 had the lowest risk of poor outcome (Q1 reference, OR 0.44, 95% CI 0.22–0.87, p = 0.019). Discussion: We found a potential non-linear relationship between TyG-i and ICH outcome, with higher odds of good prognosis in patients with intermediate values. Conclusions: TyG-i may represent a promising, low-cost and widely available biomarker that might improve prognostication in clinical practice, but further studies are needed.
- 31 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (2) , 172
Open AccessPrognostic Significance of Triglyceride Glucose Index in Intracerebral Hemorrhage
Background: The triglyceride glucose index (TyG-i), a biomarker of insulin resistance, has been associated with adverse vascular outcomes and risk stratification in several cardiovascular and cerebrovascular phenotypes. However, data on TyG-i as a prognostic marker in spontaneous intracerebral hemorrhage (ICH) remain limited. Objective: To explore the association between TyG-i and 90-day functional outcome in patients with ICH. Methods: A retrospective analysis of adult patients admitted for non-traumatic small vessel disease-related ICH at three Italian neurological institutions was conducted. TyG-i was calculated on admission as Ln[(fast triglycerides (mg/dL) × fast glucose (mg/dL))]/2. Functional outcome was measured with the modified Rankin Scale (mRS) at 90 days from the index event. TyG-i was analyzed as a continuous variable and categorized in quintiles (Q1 to Q5). Predictors of poor outcome (mRS 4–6) were investigated with multivariable logistic regression. Results: A total of 463 patients were included, of whom 197 (42.5%) had poor outcome at 90 days. TyG-i analyzed as a continuous variable was not associated with unfavorable prognosis. TyG-i analyzed as a categorical variable stratified by quintiles showed a non-linear U-shaped relationship with functional outcome; patients in Q4 had the lowest risk of poor outcome (Q1 reference, OR 0.44, 95% CI 0.22–0.87, p = 0.019). Discussion: We found a potential non-linear relationship between TyG-i and ICH outcome, with higher odds of good prognosis in patients with intermediate values. Conclusions: TyG-i may represent a promising, low-cost and widely available biomarker that might improve prognostication in clinical practice, but further studies are needed.
- Top Cited PapersOpen Access
- 9 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (6) , 2036-2043
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden ( n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93–0.96. In secondary care, the accuracies were 89–91%, the positive predictive values 89–95% and the negative predictive values 77–90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92–94% in secondary and primary care, excluding 12–17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations.
- 9 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (6) , 2036-2043
Top Cited PapersOpen AccessPlasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with cognitive symptoms from 4 independent secondary care cohorts in Malmö (Sweden, n = 337), Gothenburg (Sweden, n = 165), Barcelona (Spain, n = 487) and Brescia (Italy, n = 230), and a primary care cohort in Sweden ( n = 548). Plasma p-tau217 was primarily measured using the fully automated, commercially available, Lumipulse immunoassay. The primary outcome was AD pathology defined as abnormal cerebrospinal fluid Aβ42:p-tau181. Plasma p-tau217 detected AD pathology with areas under the receiver operating characteristic curves of 0.93–0.96. In secondary care, the accuracies were 89–91%, the positive predictive values 89–95% and the negative predictive values 77–90%. In primary care, the accuracy was 85%, the positive predictive values 82% and the negative predictive values 88%. Accuracy was lower in participants aged ≥80 years (83%), but was unaffected by chronic kidney disease, diabetes, sex, APOE genotype or cognitive stage. Using a two-cutoff approach, accuracies increased to 92–94% in secondary and primary care, excluding 12–17% with intermediate results. Using the plasma p-tau217:Aβ42 ratio did not improve accuracy but reduced intermediate test results (≤10%). Compared with a high-performing mass-spectrometry-based assay for percentage p-tau217, accuracies were comparable in secondary care. However, percentage p-tau217 had higher accuracy in primary care and was unaffected by age. In conclusion, this fully automated p-tau217 test demonstrates high accuracy for identifying AD pathology. A two-cutoff approach might be necessary to optimize performance across diverse settings and subpopulations.
- Open Access
- 7 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7457
Unveiling New Genetic Variants Associated with Age at Onset in Alzheimer’s Disease and Frontotemporal Lobar Degeneration Due to C9orf72 Repeat Expansions
Alzheimer’s disease (AD) and Frontotemporal lobar degeneration (FTLD) represent the most common forms of neurodegenerative dementias with a highly phenotypic variability. Herein, we investigated the role of genetic variants related to the immune system and inflammation as genetic modulators in AD and related dementias. In patients with sporadic AD/FTLD (n = 300) and GRN/C9orf72 mutation carriers (n = 80), we performed a targeted sequencing of 50 genes belonging to the immune system and inflammation, selected based on their high expression in brain regions and low tolerance to genetic variation. The linear regression analyses revealed two genetic variants: (i) the rs1049296 in the transferrin (TF) gene, shown to be significantly associated with age at onset in the sporadic AD group, anticipating the disease onset of 4 years for each SNP allele with respect to the wild-type allele, and (ii) the rs7550295 in the calsyntenin-1 (CLSTN1) gene, which was significantly associated with age at onset in the C9orf72 group, delaying the disease onset of 17 years in patients carrying the SNP allele. In conclusion, our data support the role of genetic variants in iron metabolism (TF) and in the modulation of the calcium signalling/axonal anterograde transport of vesicles (CLSTN1) as genetic modulators in AD and FTLD due to C9orf72 expansions.
- 7 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7457
Open AccessUnveiling New Genetic Variants Associated with Age at Onset in Alzheimer’s Disease and Frontotemporal Lobar Degeneration Due to C9orf72 Repeat Expansions
Alzheimer’s disease (AD) and Frontotemporal lobar degeneration (FTLD) represent the most common forms of neurodegenerative dementias with a highly phenotypic variability. Herein, we investigated the role of genetic variants related to the immune system and inflammation as genetic modulators in AD and related dementias. In patients with sporadic AD/FTLD (n = 300) and GRN/C9orf72 mutation carriers (n = 80), we performed a targeted sequencing of 50 genes belonging to the immune system and inflammation, selected based on their high expression in brain regions and low tolerance to genetic variation. The linear regression analyses revealed two genetic variants: (i) the rs1049296 in the transferrin (TF) gene, shown to be significantly associated with age at onset in the sporadic AD group, anticipating the disease onset of 4 years for each SNP allele with respect to the wild-type allele, and (ii) the rs7550295 in the calsyntenin-1 (CLSTN1) gene, which was significantly associated with age at onset in the C9orf72 group, delaying the disease onset of 17 years in patients carrying the SNP allele. In conclusion, our data support the role of genetic variants in iron metabolism (TF) and in the modulation of the calcium signalling/axonal anterograde transport of vesicles (CLSTN1) as genetic modulators in AD and FTLD due to C9orf72 expansions.